Aims Durability of transcatheter aortic valve implantation (TAVI) is key to its expansion. We sought to identify incidence of valve thrombosis and predictors of valve thrombosis in our single centre with associated coagulation testing pre-TAVI and post-TAVI.
Methods and results This single-centre observational study comprised patients undergoing transfemoral TAVI discussed in the Heart Team meeting . Patients were followed up with echocardiography at 120 days to identify incidence of elevated transvalvular gradient and multivariable analysis was performed to identify factors associated with an increased odds of developing valve thrombosis. In addition, 11 patients underwent baseline, day 1 and day 120 post-TAVI coagulation testing. Between August 2017 and August 2019, 437 consecutive patients underwent transfemoral TAVI. Of these patients, 207/437 (47.4%) had 3-month follow-up echo data available and were analysed. Of these patients, 26/207 (12.6%) had elevated transvalvular gradients. These patients tended to be younger (80±14 vs 83±6 years; p=0.047) with a lower ejection fraction (49±13 vs 54%±11%; p=0.021), with a greater proportion of the population experiencing atrial fibrillation (14/21, 54% vs 68/181, 38%; p=0.067). Following multivariable analysis, there remained a trend towards higher eccentricity index associated with elevated gradients. Baseline (pre-TAVI) elevation of thrombin antithrombin levels (56±63; reference range 1.0–4.1 ng/L) and PF 1+2 (791±632; reference range 69–229 ng/mL) normalised at 120 days post-TAVI
Conclusion This study demonstrated that in the cohort of patients undergoing transfemoral TAVI in our centre: younger age, poor ejection fraction, atrial fibrillation and increased baseline eccentricity of the aortic valve annulus were present to a greater extent in patients exhibiting elevated transvalvular gradients at 3-month follow-up. Further work is required to delineate the extent of coagulation derangement and confirm predictors of thrombosis.
- aortic valve stenosis
- heart valve diseases
- transcatheter aortic valve replacement
Data availability statement
All data relevant to the study are included in the article or uploaded as online supplemental information.
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Statistics from Altmetric.com
What is already known about this subject?
Baseline coagulation derangement has not been well characterised in the aortic stenotic population and little is known regarding the real-world incidence of transcatheter aortic valve implantation (TAVI) leaflet thrombosis.
What does this study add?
This study demonstrated that in the cohort of patients undergoing transfemoral TAVI in our centre: younger age, poor ejection fraction, atrial fibrillation and increased baseline eccentricity of the aortic valve annulus were present to a greater extent in patients exhibiting elevated transvalvular gradients.
How might this impact on clinical practice?
Understanding predictors of valve thrombosis will enable us to tailor anticoagulation therapy appropriately post-TAVI.
Transcatheter aortic valve implantation (TAVI) has become an important alternative to surgical aortic valve replacement (sAVR). TAVI demand is expected to increase exponentially with an ageing population. Early clinical outcomes are at least equivalent, if not superior to sAVR, regardless of risk score.1 Durability is key if TAVI is to expand into the younger population. There has been recent concern as to the detection of TAVI leaflet thrombosis in up to 15% of patients at follow-up. TAVI thrombosis has been reported to lead to early valve failure presenting as elevated transvalvular gradients and dyspnoea, thromboembolism and stroke. Low cardiac output states can reduce transvalvular blood flow thus promoting stasis. The impact of low flow is well demonstrated in mitral prostheses, which carry a threefold increased risk of thrombosis in comparison with aortic prostheses.2 Artificial valve leaflets, local tissue injury during the procedure and persistence of the native calcified valve leaflets increase tissue factor release thereby inducing local activation of the extrinsic coagulation pathway. This is in contrast to the normal endothelium, which produce an antithrombotic milieu. Chronic kidney disease, anaemia and obesity, which occur more commonly in the high-risk TAVI population are also associated with prothrombotic states.3 However, baseline coagulation derangement has not been well characterised in the aortic stenotic population and little is known regarding the real-world incidence of TAVI thrombosis. Furthermore, routine anticoagulation post-TAVI has been associated with harm. It is, therefore, essential to determine risk factors and contributors to valve thrombosis. In this observational study, consecutive patients undergoing transfemoral TAVI were examined in our single centre over a 2-year period, with assessment of baseline characteristics and follow-up echocardiography to identify the incidence of elevated transvalvular gradient at 3 months compared with baseline postprocedure with a view to determining predictors of valve thrombosis.4 In addition, we performed coagulation tests periprocedurally and at 3 months in a subset of patients to establish baseline and postprocedural coagulation derangement in this cohort.
Study design and population
This prospective observational study was conducted at a single centre: St Thomas Hospital, London, UK. This study included all consecutive patients that underwent successful transfemoral TAVI procedure between August 2017 and August 2019. Prior to TAVI implantation, all patients were discussed in a dedicated Heart Team Meeting.
To identify baseline coagulation derangement in the aortic stenotic population and the duration of coagulation derangement post TAVI, a random sample of 11 patients awaiting TAVI was examined. Blood test time points were as follows: on admission prior to TAVI implantation, day 1 post-TAVI and at 3 months post-TAVI. The coagulation testing comprised haemoglobin level (Hb), mean corpuscular volume, white cell count (WCC), platelet count (PLT), thrombin antithrombin (TAT), D-dimer, lactate dehydrogenase (LDH), fibrinogen, prothrombin factors 1+2 (PF1 +2), international normalised ratio, activated prothrombin time. TAT and PF1 +2 were selected as they represent thrombin generation. D-dimer is an indicator of thrombosis and endogenous fibrinolytic activity. LDH is a marker of haemolysis.
In order to identify the incidence of elevated transvalvular gradients, follow-up echocardiography was performed 3 months postprocedure and compared with the immediate postprocedure echocardiogram. Patients were deemed to have leaflet thrombosis based on both clinical assessment and fulfilment of the following criteria: elevated mean bioprosthetic valve gradient of greater than 10 mm Hg at 3 months compared with the immediate post-TAVI echocardiogram (structural valve deterioration defined according to ESC guidance) with accompanied restricted leaflet motion on echocardiogram at 3 months follow-up.4 For the purposes of analysis at 3 months, patients were classified according to the presence or absence of elevated transvalvular gradients compared with the immediate post-TAVI echocardiogram. Baseline characteristics collected included cardiovascular risk factors, presence of antiplatelet and/or anticoagulation therapy, New York Heart Association (NYHA) Class, ejection fraction and pre-TAVI CT parameters including annulus area and eccentricity index (defined as the major annulus diameter/minor annulus diameter as a percentage).
In reference to baseline characteristics and potential risk factors associated with elevated transvalvular gradients, categorical data were presented as counts and percentages, and comparison between groups (presence or absence of elevated transvalvular gradients) performed using χ2 test or Fisher’s exact test; continuous data of normal distribution were presented as mean±SD and comparison between groups performed using independent t-test. Statistical comparison of serial coagulation testing (pre-TAVI, post-TAVI day 1 and day 120) was performed using one-way analysis of variance; thereafter, analysis of specific sample pairs (paired differences) was performed compared using paired t-test.
Univariate analysis was used to identify potential predictors of elevated transvalvular gradient. Variables associated with a p<0.05 were then included in the multivariate analysis. The variance inflation factor was used to determine colinearity using standardised cut-offs. To determine clinical predictors of valve thrombosis, the covariates entered into the equation were: age, presence of atrial fibrillation, ejection fraction, postprocedure echo gradient and the eccentricity index. Adjusted ORs (OR) with 95% CIs are reported. All p values were two sided with a significance threshold p<0.05. Statistical analysis was performed using SPSS V.24.0 (IBM).
Between August 2017 and August 2019, 437 consecutive patients underwent transfemoral TAVI. Of these patients, 207/437 (47.4%) had 3 months follow-up echo data available and were analysed. Of these patients, 26/207 (12.6%) had elevated transvalvular gradients. Baseline characteristics including demographics, cardiovascular risk factors, NYHA class at presentation and ejection fraction are provided in table 1. Patients with an elevated transvalvular gradient at follow-up (mean gradient >10 mmHg compared with immediately post-TAVI) tended to be younger (80±14 vs 83±6 years; p=0.047) with a lower ejection fraction (49±13 vs 54%±11%; p=0.021), with a greater proportion of the population experiencing atrial fibrillation (14/21, 54% vs 68/181, 38%; p=0.067) when compared with those without elevated gradients. Pre-TAVI CT parameters and immediate post-TAVI echo parameters are shown in table 2. Patients with an elevated transvalvular gradient at follow-up demonstrated higher eccentricity of the annulus (21±4 vs 18%±6%; p=0.019) and lower echo-derived bioprosthetic aortic valve gradients (9.4±4.5 vs 12.5±6; p=0.003) and echo-derived peak bioprosthetic aortic valve velocity (1.9±0.5 vs 2.3±0.5 m/s; p<0.001). There were no other observed between the two groups.
Significant variables were used to perform multivariable logistic regression analysis. The outcomes are reported in table 3. Multivariable analysis did not demonstrate an association between ejection fraction, mean gradient, peak velocity, atrial fibrillation and elevated transvalvular gradients. However, there remained a trend towards older age being negatively associated with elevated transvalvular gradients (OR 0.925, 95% CI 0.836 to 1.024; p=0.132). There was also a trend toward higher eccentricity index being associated with elevated transvalvular gradients (OR 1.107, 95% CI 0.983 to 1.247; p=0.095).
The results of serial coagulation testing are presented in table 4 and depicted graphically in figure 1. Of the 11 patients, serial blood testing was performed in nine patients (two patients could not perform follow-up tests due to limited mobility). Coagulation testing demonstrated baseline (pre-TAVI) elevation of TAT levels (56±63; reference range 1.0–4.1 ng/L), and PF 1+2 (791±632; reference range 69–229 ng/mL) which normalised by 3 months, however, this did not reach significance. As expected, there was a postprocedure decrease in Hb (112±18.2 vs 118±21.5; p=0.082) and platelets (169±52.2 vs 199±54.9; p=0.009) with an increase in WCC (10.0±3.3 vs 7.1±1.6, p=0.003) and D-dimer (1.86±0.79 vs 0.49±0.27, p=0.046) levels. LDH remained slightly elevated 3 months post-TAVI.
This study demonstrated that in the cohort of patients undergoing transfemoral TAVI in our centre: younger age, poor ejection fraction, atrial fibrillation and increased baseline eccentricity of the aortic valve annulus were present to a greater extent in patients exhibiting elevated transvalvular gradients at 3 months follow-up. Multivariable analysis also demonstrated a trend towards an increased probability of elevated transvalvular gradients in younger patients with a higher eccentricity index. This study also demonstrated a baseline derangement coagulation tests in patients with aortic stenosis undergoing TAVI with near normalisation of these coagulation factors at 3 months following the TAVI procedure.
Previous work has demonstrated a potential association between smoking, diabetes and valve thrombosis.5 These factors have been previously shown to be associated with a prothrombotic state. We were unable to demonstrate a similar association, but this may have been due to smaller numbers in our study cohort. Prior work has also demonstrated post-TAVI eccentricity to be associated with valve thrombosis previously.5 This is similar to our findings although we measured eccentricity preprocedure but it would be reasonable to conclude that the two are related with preprocedure eccentricity likely to influence TAVI valve expansion in the presence of calcification. We are, however, limited by the absence of post-TAVI CT assessment to confirm this association. Patients with a lower ejection fraction are likely to exhibit slower flow across the TAVI valve, which is a known factor in the triad of thrombosis. Interestingly, lower postprocedural mean gradient was also associated with thrombosis, however, this is more likely to be a reflection of reduced left ventricular function.
Baseline coagulation derangement was identified in patients pre-TAVI. This is likely secondary to tissue factor release from the native valve leaflets which can persist post-TAVI. PF 1+2 and TAT levels are both markers of thrombin generation, both of which were elevated preprocedure and these tended to normalise by 3 months, which could reflect valve endothelialisation. The increase in LDH post-TAVI follows a periprocedural drop in Hb and the raised D-dimer levels is due to the procedural insult and activation of the clotting cascade. Postmortem studies have suggested endothelialisation of the TAVI leaflets at 120 days, however, our results would suggest that valve endothelialisation is multifactorial and varies between individuals.
The recently published trial of rivaroxaban following TAVI demonstrated that patients without an established indication for oral anticoagulation experienced a higher risk of death or thromboembolic complications and bleeding than an antiplatelet-based strategy.6 This highlights that routine use of anticoagulation may cause harm but supports the need to identify predictors of valve thrombosis.
This was a single-centre study. The biomarker screening arm was limited by its small size. Post-TAVI CT scanning was not performed and would have added further useful information.
This study demonstrated that in the cohort of patients undergoing transfemoral TAVI in our centre: younger age, poor ejection fraction, atrial fibrillation and increased baseline eccentricity of the aortic valve annulus were present to a greater extent in patients exhibiting elevated transvalvular gradients at 3-month follow-up. Further work is essential to examine the extent of coagulation derangement and confirm predictors of thrombosis.
Data availability statement
All data relevant to the study are included in the article or uploaded as online supplemental information.
Ethical approval was granted by local Research Ethics Committee and Health Research Authority (20/EM/0192).
Contributors All authors have contributed substantially to the manuscript, fulfilling the criteria as stated in the ICMJE guidance. In light of the additional work, further full year of data collection and detailed revised statistical analysis, a number of additional coauthors have been added: JG, UD, CY, GL and NA. There was no external assistance in writing the manuscript. There is no overlap with previous publications: the manuscript, figures, tables and data are all original work and is not under consideration elsewhere.
Funding This study was supported British Medical Association Foundation for Medical Research Josephine Lansdell Grant (T Patterson) and a British Heart Foundation Clinical Research Training Fellowship (FS/14/11/30526 T Patterson).
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.